Jason A. Efstathiou MD PhD
Professor of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital
Join to View Full Profile
Massachusetts General Hospital55 Fruit StreetBoston, MA 02114
Phone+1 617-726-5866
Dr. Efstathiou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2004 - 2008- Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 2003 - 2004
Harvard Medical SchoolClass of 2003
Certifications & Licensure
ME State Medical License 2020 - 2027
NH State Medical License 2021 - 2027
MA State Medical License 2008 - 2026
RI State Medical License 2021 - 2026
American Board of Radiology Radiation Oncology
Clinical Trials
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
- Proton Radiotherapy for Stage I, IIA, and IIB Seminoma Start of enrollment: 2012 Mar 01
- Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer Start of enrollment: 2012 Jul 25
- Join now to see all
Publications & Presentations
PubMed
- PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance.Andrew Gusev, Florian Rumpf, Dimitar Zlatev, Jeffrey K Twum-Ampofo, John L Gore
Urologic Oncology. 2025-12-01 - Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation T...Daniel A Hamstra, James J Dignam, Deborah W Bruner, M Dror Michaelson, François Bachand
International Journal of Radiation Oncology, Biology, Physics. 2025-12-01 - Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy.David J Konieczkowski, Keisuke Otani, Zoe Guan, Michael R Drumm, Yukako Otani
NPJ Precision Oncology. 2025-12-01
Journal Articles
- Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder CancerJason Efstathiou, MD, JAMA
- Impact of Interfractional Motion on Hypofractionated Pencil Beam Scanning Proton Therapy and VMAT Delivery for Prostate CancerA L Zietman, Y Wang, J A Efstathiou, F H Khan, Medical Physics
- Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological FeaturesRahul D. Tendulkar, Kevin L. Stephans, Stanley L. Liauw, Robert B. Den, Shre Agrawal, Jason A. Efstathiou, Thomas M. Pisansky, Jason W. Hearn, Jef M. Michalski, Drew M..., JAMA
Authored Content
- PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason EfstathiouSeptember 2024
- Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre ZlottaJune 2023
- Are We Ready to Change Management Based on Next-Generation Imaging? YES: APCCC 2022 Presentation Jason EfstathiouAugust 2022
Press Mentions
Biden Did Not Get Prostate Cancer Diagnosis Before Last Week, Spokesman SaysMay 20th, 2025- What to Know About Prostate Cancer After Former President Joe Biden's DiagnosisMay 19th, 2025
- Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate CancerApril 4th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
